H-Ile-His-NH2 | 102522-23-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-Ile-His-NH2
• 英文别名: (2S,3S)-2-amino-N-[(2S)-1-amino-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-3-methylpentanamide
• CAS: 102522-23-6
• 化学式: C₁₂H₂₁N₅O₂
• 分子量: 267.331
• InChiKey: PWFNQZONFPMCIG-HGNGGELXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  127
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  H-Ile-His-NH2 在 palladium on activated charcoal 氢气 、 1-羟基苯并三唑一水物 、 N,N'-二环己基碳二亚胺 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 120.5h， 生成 (2S,4S,5S)-5-[(S)-2-[(S)-2-(2,2-Dimethyl-propionylamino)-3-phenyl-propionylamino]-3-(1H-imidazol-4-yl)-propionylamino]-4-hydroxy-2-isopropyl-7-methyl-octanoic acid {(1S,2S)-1-[(S)-1-carbamoyl-2-(1H-imidazol-4-yl)-ethylcarbamoyl]-2-methyl-butyl}-amide
  参考文献：
  名称：

  Synthesis and biological activity of some transition-state inhibitors of human renin

  摘要：

  A series of renin inhibitors containing the dipeptide transition state mimics (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-7-methyloctanoic acid (Leu (OH)/Val) and (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-6-cyclohexylhexanoic acid (CHa /(OH)/Val) was prepared. A structure-activity study with Boc-Phe-His-Leu (OH)/Val-Ile-His-NH2 (8a) as starting material led to N-[(2S)-2-[(tert-butylsulfonyl)methyl]-3-phenylpropionyl]-His-Cha (OH)/ Val- NHC4H9-n (8i) which has the length of a tetrapeptide and contains only one natural amino acid. Compound 8i had an IC50 of 2 x 10(-9) M against human renin and showed high enzyme specificity; IC50 values against the related aspartic proteinases pepsin and cathepsin D were (8 x 10(-6) and 3 x 10(-6) M, respectively). In salt-depleted marmosets, 8i inhibited plasma renin activity PRA and lowered blood pressure for up to 2 h after oral administration of a dose of 10 mg/kg.

  DOI：

  10.1021/jm00117a027
• 作为产物：
  描述：

  Z-Ile-His-OMe 在 palladium on activated charcoal 氨 、 氢气 作用下， 以 甲醇 、 水 为溶剂， 25.0 ℃ 、110.31 kPa 条件下， 反应 15.0h， 生成 H-Ile-His-NH2
  参考文献：
  名称：

  Renin inhibitors. Synthesis of transition-state analog inhibitors containing phosphorus acid derivatives at the scissile bond

  摘要：

  The synthesis of five amino phosphorus derivatives, 1a-e, is described. The derivatives were incorporated into a series (18) of analogues of the 5-14 portion of angiotensinogen, in most cases at the scissile Leu-Val bond. The resultant compounds were tested in vitro for their ability to inhibit human plasma renin. Replacement of the scissile bond with the phosphinic analogue of Leu10-Val11 (1b) gave the most potent inhibitors, having IC50 = 7.5 x 10(-8) M for H-Pro-His-Pro-Phe-His-(1b)-Ile-His-Lys-OH and IC50 = 1.0 x 10(-7) M for Z-Arg-Arg-Pro-Phe-His-(1b)-Ile-His-NH2. The shorter phosphonic acid sequence Z-Pro-Phe-His-(1d) retained biological activity with an IC50 = 6.4 x 10(-6) M.

  DOI：

  10.1021/jm00127a041

文献信息

• [EN] PTHR1 RECEPTOR COMPOUNDS<br/>[FR] COMPOSÉS DE RÉCEPTEURS PTHR1
  申请人：ANCHOR THERAPEUTICS INC

  公开号：WO2010053548A2

  公开（公告）日：2010-05-14

  The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHRl, also known as parathyroid hormone/parathyroid hormone related protein receptor. The PTHRl compounds are derived from the intracellular loops and domains of the PTHRl receptor. The invention also relates to the use of these PTHRl receptor compounds and pharmaceutical compositions comprising the PTHRl receptor compounds in the treatment of diseases and conditions associated with PTHRl receptor modulation, such as osteoporosis; humoral hypercalcemia of malignancy; osteolytic and osteoblastic metastasis to bone; primary and secondary hyperparathyroidism associated increase in bone absorption; vascular calcification; psychiatric disorders and cognitive disorders associated with hyperparathyroidism; dermatological disorders; and excess hair growth.